Liver Cancer Markers
For hepatocellular carcinoma (HCC), use alpha-fetoprotein (AFP) combined with ultrasound for surveillance, though AFP alone is inadequate as a screening test; for cholangiocarcinoma, measure a combination of CA 19-9, CEA, and CA-125, recognizing that no single marker is specific or sufficiently sensitive for diagnosis.
Hepatocellular Carcinoma Markers
Alpha-Fetoprotein (AFP)
AFP is the most studied serological marker for HCC, but its performance characteristics are problematic 1:
- Sensitivity is only 60% at the optimal cut-off of 20 ng/mL, meaning 40% of HCCs would be missed
- At higher cut-offs (200 ng/mL), sensitivity drops to just 22%
- The positive predictive value is only 41.5% in typical clinic populations with 5% HCC prevalence
- AFP >200 ng/mL does have very high positive predictive value for HCC in cirrhotic patients with a liver mass 1
Critical caveat: AFP is inadequate as a standalone screening test but remains useful for risk stratification and diagnosis confirmation 1.
Surveillance Strategy for HCC
Perform abdominal ultrasound every 6 months with or without AFP in at-risk patients 2. The combination increases detection rates but also increases costs and false-positive rates 1. Ultrasound alone has 65-80% sensitivity and >90% specificity, superior to any serological test 1.
Other HCC Markers
- Des-gamma-carboxy prothrombin (DGCP/PIVKA II): Insufficient evidence for routine surveillance use; may indicate portal vein invasion (suggesting late disease, not early) 1
- AFP-L3 fraction, alpha-fucosidase, glypican 3: Not adequately investigated for clinical recommendation 1
Cholangiocarcinoma Markers
No Specific Diagnostic Markers Exist
There are no tumor markers specific for cholangiocarcinoma 3. All markers have low sensitivity and specificity but can be useful when diagnostic doubt exists 3.
CA 19-9 (Most Widely Used)
- Elevated in up to 85% of cholangiocarcinoma patients 3
- CA 19-9 >100 U/mL has 75% sensitivity and 80% specificity in PSC patients 3
- Major limitation: Elevated in obstructive jaundice without malignancy; persistently raised levels after biliary decompression suggest malignancy 3
- Cannot discriminate between cholangiocarcinoma, pancreatic, or gastric malignancy 3
- Also elevated in severe hepatic injury from any cause 3
CEA (Carcinoembryonic Antigen)
- Raised in approximately 30% of cholangiocarcinoma patients 3
- Also elevated in inflammatory bowel disease, biliary obstruction, other tumors, and severe liver injury 3
CA-125
- Elevated in 40-50% of cholangiocarcinoma patients 3
- May signify peritoneal involvement but requires further study 3
Recommended Approach for Cholangiocarcinoma
Measure a combination of serum tumor markers (CA 19-9, CEA, CA-125) where diagnostic doubt exists 3. However, diagnosis should not rest solely on serum tumor marker measurements 3.
There is no evidence that tumor markers are useful for monitoring tumor progression in cholangiocarcinoma 3.
Distinguishing HCC from Cholangiocarcinoma
When differentiating between these two primary liver cancers:
- AFP negativity with CA 19-9 or CA-242 positivity strongly suggests cholangiocarcinoma over HCC 4
- The combination of AFP(-) and CA242(+) provides 94.3% specificity and 78.5% accuracy for distinguishing intrahepatic cholangiocarcinoma from HCC 4
- AFP is significantly elevated in HCC; CA 19-9 is markedly elevated in cholangiocarcinoma 5
Advanced Disease Markers
With advanced disease in cholangiocarcinoma, non-specific systemic markers may be altered 3:
- Reduced albumin
- Reduced hemoglobin
- Elevated lactate dehydrogenase (LDH)
Key Clinical Pitfalls
- Never rely on AFP alone for HCC screening—its sensitivity is inadequate 1
- CA 19-9 elevation in cholangiocarcinoma can be falsely positive in obstructive jaundice; recheck after biliary decompression 3
- No cholangiocarcinoma marker is specific—always use in conjunction with imaging and clinical context 3
- Tumor markers cannot monitor cholangiocarcinoma progression—do not use serially for this purpose 3